Last update 01 Nov 2024
Lilly del Caribe, Inc.
Subsidiary Company|
Puerto Rico
Last update 01 Nov 2024
Overview
Tags
Other Diseases
Otorhinolaryngologic Diseases
Immune System Diseases
Small molecule drug
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
在使用甘精胰岛素单用或联合二甲双胍和/或SGLT-2抑制剂后血糖控制不佳的2型糖尿病成人受试者中评价每日一次口服orforglipron与安慰剂相比的有效性和安全性的3期、随机、双盲研究（ACHIEVE-5）
[Translation] A phase 3, randomized, double-blind study evaluating the efficacy and safety of once-daily oral orforglipron compared with placebo in adults with type 2 diabetes who have inadequate glycemic control on insulin glargine alone or in combination with metformin and/or an SGLT-2 inhibitor (ACHIEVE-5)
在二甲双胍治疗后血糖控制不佳的2型糖尿病成人受试者中评价每日一次口服orforglipron与达格列净相比的有效性和安全性的3期,随机,开放标签研究（ACHIEVE-2）
[Translation] A phase 3, randomized, open-label study evaluating the efficacy and safety of once-daily oral orforglipron compared with dapagliflozin in adults with type 2 diabetes who have inadequate glycemic control on metformin (ACHIEVE-2)
在二甲双胍治疗后血糖控制不佳的2型糖尿病成人受试者中评价每日一次口服LY3502970与口服司美格鲁肽相比的有效性和安全性的3期、随机、开放标签研究（ACHIEVE-3）
[Translation] A phase 3, randomized, open-label study evaluating the efficacy and safety of once-daily oral LY3502970 compared with oral semaglutide in adult subjects with type 2 diabetes who have inadequate glycemic control on metformin (ACHIEVE-3)
100 Clinical Results associated with Lilly del Caribe, Inc.
Login to view more data
Login to view more data
100 Deals associated with Lilly del Caribe, Inc.
Login to view more data
100 Translational Medicine associated with Lilly del Caribe, Inc.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 25 Nov 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 3 Clinical
1
1
Approved
Other
1
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free